Header

Our Pipeline

We aim to address key drivers of cancer and turn cold tumors hot, with a diverse range of mode of actions and smart combinations.

LATEST DEVELOPMENT PHASE (AS OF MARCH 2024)

Download Pipeline PDF

Reset all filters

Phase III: DDLPS
Phase II: BTC
Phase 0/I: GBM

Phase III: NSCLC

Phase II: SCLC / other NECs
Phase I: SCLC / NECs expressing DLL3

Phase I: Solid tumors

Phase I: Solid tumors

Phase I: Solid tumors

Phase I: Solid tumors

Phase I: Solid tumors

Phase I: PDAC

Phase I: Solid tumors

Phase I: Gastric, esophageal, GEJ adenocarcinoma

Phase I: Solid tumors

Phase I: Solid tumors

Phase I: Solid tumors

Phase I: Solid tumors

Phase I: Solid tumors

Phase I: Solid tumors

Phase I: PDAC

Phase I: Solid tumors

Download Pipeline PDF

  1. ClinicalTrials.gov. NCT05218499. https://clinicaltrials.gov/study/NCT05218499 (Accessed: February 2024)

  2. ClinicalTrials.gov. NCT05512377. https://clinicaltrials.gov/study/NCT05512377 (Accessed: February 2024)

  3. ClinicalTrials.gov. NCT04886804. https://clinicaltrials.gov/study/NCT04886804 (Accessed: February 2024)

  4. ClinicalTrials.gov. NCT04429087. https://clinicaltrials.gov/study/NCT04429087 (Accessed: February 2024)

  5. ClinicalTrials.gov. NCT05882058. https://clinicaltrials.gov/study/NCT05882058 (Accessed: February 2024)

  6. ClinicalTrials.gov. NCT04752215. https://clinicaltrials.gov/study/NCT04752215 (Accessed: February 2024)

  7. ClinicalTrials.gov. NCT03697304. https://clinicaltrials.gov/study/NCT03697304 (Accessed: February 2024)

  8. ClinicalTrials.gov. NCT02952248. https://clinicaltrials.gov/study/NCT02952248 (Accessed: February 2024)

  9. ClinicalTrials.gov. NCT04958239. https://clinicaltrials.gov/study/NCT04958239 (Accessed: February 2024)

  10. ClinicalTrials.gov. NCT03990233. https://clinicaltrials.gov/study/NCT03990233 (Accessed: February 2024)

  11. ClinicalTrials.gov. NCT05249426. https://clinicaltrials.gov/study/NCT05249426 (Accessed: February 2024)

  12. ClinicalTrials.gov. NCT05068102. https://clinicaltrials.gov/study/NCT05068102 (Accessed: February 2024)

  13. ClinicalTrials.gov. NCT05327946. https://clinicaltrials.gov/study/NCT05327946 (Accessed: February 2024)

  14. ClinicalTrials.gov. NCT05155332. https://clinicaltrials.gov/study/NCT05155332 (Accessed: February 2024)

  15. ClinicalTrials.gov. NCT05839600. https://clinicaltrials.gov/study/NCT05839600 (Accessed: February 2024)

  16. ClinicalTrials.gov. NCT05846516. https://clinicaltrials.gov/study/NCT05846516 (Accessed: February 2024)

  17. ClinicalTrials.gov. NCT05471856. https://clinicaltrials.gov/study/NCT05471856 (Accessed: February 2024)

  18. ClinicalTrials.gov. NCT06056024. https://clinicaltrials.gov/study/NCT06056024 (Accessed: February 2024)

  19. ClinicalTrials.gov. NCT03964233. https://clinicaltrials.gov/study/NCT03964233 (Accessed: February 2024)

Share this page

BTC, biliary tract cancer; CD, cluster of differentiation; CRC, colorectal cancer; DDLPS, dedifferentiated liposarcoma; DLL3, Delta-like 3; FAP, fibroblast activation protein; GBM, glioblastoma; GEJ, gastroesophageal junction; GI, gastrointestinal; GP, glycoprotein; HER2, human epidermal growth factor receptor 2; MDM2, murine double minute 2 protein; NEC, neuroendocrine carcinoma; NSCLC, non-small-cell lung cancer; SCLC, small-cell lung cancer; SIRPα, signal-regulatory protein alpha; STING, small molecule agonist of the stimulator of interferon genes; TKI, tyrosine kinase inhibitor; VSV, vesicular stomatitis virus.